Yulin Lu
![](https://econcrimecompliance-ch.com/sites/default/files/styles/panopoly_image_square/public/speakers/headshot_24.png?itok=awUjBKmK&c=7b8d8f5939b9a4145c680e3fe42886e1)
Jeff McKenna
Walker Graham
Nathaniel
![](https://econcrimecompliance-ch.com/sites/default/files/styles/panopoly_image_square/public/speakers/gregh.jpg?itok=dJ8sQP0M&c=8debe8b45e8aa8069f38c8b2485265ac)
Greg Hollingworth
Max Johansen
C. Vivek Lal
![](https://econcrimecompliance-ch.com/sites/default/files/styles/panopoly_image_square/public/speakers/1640730279065.png?itok=GQFZmamD&c=fca690c28f3148226ba10bf3df52390c)
Karen Miller
Initial introduction to molecular glues during tenure at Celgene from 2010-2015 where she was a key member on the IMiD “mechanism of action” discovery team. Work here directly contributed to the clinical development of pomalidomide and downstream mechanistic discovery of IMiDs including in-house identification of Ikaros, Aiolos, and GSPT1 as neosubstrates of various IMiD molecules. Subsequently, left Celgene to obtain her PhD from The Scripps Research Institute under the tutelage of Dr. Michael McHeyzer-Williams, focusing on adaptive immunity through germinal center formation and evolution. Following completion of her degree in 2021, she returned to the TPD space, moving to Biotheryx where she is currently the biology lead for both the BTX-1188 and Neosubstrate Discovery projects.